T14

3-{7-(trifluoromethyl)-5-[2-(trifluoromethyl)phenyl]-1H-benzimidazol-2-yl}-1-oxa-2-azaspiro[4.5]dec-2-ene

Created:	2019-03-08
Last modified:	2019-09-18

Find Related PDB Entry
4 entries where T14 is found as a standalone ligand

Find related ligands:

Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	52
Chiral Atom Count	0
Bond Count	56
Aromatic Bond Count	16

2D diagram of T14

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	3-{7-(trifluoromethyl)-5-[2-(trifluoromethyl)phenyl]-1H-benzimidazol-2-yl}-1-oxa-2-azaspiro[4.5]dec-2-ene
Systematic Name (OpenEye OEToolkits)	3-[7-(trifluoromethyl)-5-[2-(trifluoromethyl)phenyl]-1~{H}-benzimidazol-2-yl]-1-oxa-2-azaspiro[4.5]dec-2-ene
Formula	C₂₃ H₁₉ F₆ N₃ O
Molecular Weight	467.407
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	ACDLabs	12.01	C(F)(F)(c1ccccc1c5cc(C(F)(F)F)c4nc(C=2CC3(ON=2)CCCCC3)nc4c5)F
SMILES	CACTVS	3.385	FC(F)(F)c1cc(cc2nc([nH]c12)C3=NOC4(CCCCC4)C3)c5ccccc5C(F)(F)F
SMILES	OpenEye OEToolkits	2.0.7	c1ccc(c(c1)c2cc(c3c(c2)nc([nH]3)C4=NOC5(C4)CCCCC5)C(F)(F)F)C(F)(F)F
Canonical SMILES	CACTVS	3.385	FC(F)(F)c1cc(cc2nc([nH]c12)C3=NOC4(CCCCC4)C3)c5ccccc5C(F)(F)F
Canonical SMILES	OpenEye OEToolkits	2.0.7	c1ccc(c(c1)c2cc(c3c(c2)nc([nH]3)C4=NOC5(C4)CCCCC5)C(F)(F)F)C(F)(F)F
InChI	InChI	1.03	InChI=1S/C23H19F6N3O/c24-22(25,26)15-7-3-2-6-14(15)13-10-16(23(27,28)29)19-17(11-13)30-20(31-19)18-12-21(33-32-18)8-4-1-5-9-21/h2-3,6-7,10-11H,1,4-5,8-9,12H2,(H,30,31)
InChIKey	InChI	1.03	VSMFCZZEKTVDHM-UHFFFAOYSA-N

Related Resource References

Resource Name	Reference
Pharos	CHEMBL1650511
PubChem	135883253
ChEMBL	CHEMBL1650511

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.